We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ALL

News List

First children set to receive Novartis’ Kymriah pharmatimes
November 28, 2018
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
FDA expands approval of Blincyto for treatment of B-cell precursor ALL europeanpharmaceuticalreview
April 09, 2018
The FDA has granted accelerated approval to Blincyto to treat adults and children with B-cell precursor acute lymphoblastic leukaemia (ALL)…
Pfizer’s Besponsa gets FDA approval for treatment of B-cell precursor ALL pharmaceutical-technology
August 22, 2017
The US Food and Drug Administration has given approval for Pfizer’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
FDA Approves Besponsa for Relapsed or Refractory ALL americanpharmaceuticalreview
August 18, 2017
The U.S. Food and Drug Administration approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Previous page 1 2 Next page